Abstracts Archive - Page 1640 of 2607 - ACR Meeting Abstracts

Abstract Number: 608 • 2016 ACR/ARHP Annual Meeting
Initial Intensive Therapy of Adalimumab and Methotrexate Is Associated with Long-Term Structural Remission and Low Disease Activity after Adalimumab Discontinuation Is Maintained up to 3 Years in Japanese Patients: Hopeful-3 Study
Yoshiya Tanaka¹, Hisashi Yamanaka², Naoki Ishiguro³, Nobuyuki Miyasaka⁴, Katsuyoshi Kawana⁵, Naoki Agata⁵ and Tsutomu Takeuchi⁶, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Tokyo Women's Medical University, Tokyo, Japan, ³Department of Orthopedic Surgery, Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Japan, ⁴Tokyo Medical and Dental University, Tokyo, Japan, ⁵Abbvie GK, Tokyo, Japan, ⁶Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Methods: Of 172 patients enrolled, 135 (ADA continuation, n=61; ADA discontinuation, n=74) with DAS28–CRP at both week 52 (start of HOPEFUL-2) and week 208…
Abstract Number: 609 • 2016 ACR/ARHP Annual Meeting
Economic Impact of Adalimumab Treatment in Japanese Patients with Rheumatoid Arthritis from the Anouveau Study (Clinicaltrial.gov: NCT01346488)
Yoshiya Tanaka¹, Kiyotaka Yamazaki², Ryo Nakajima², Shuichi Komatsu³, Naoki Agata⁴, Ataru Igarashi⁵, Toshiro Tango⁶ and Tsutomu Takeuchi⁷, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Post Marketing Study Group, Medical, AbbVie GK, Tokyo, Japan, ³Scientific Project Manager Group, Medical, AbbVie GK, Tokyo, Japan, ⁴Medical Communication, Medical, AbbVie GK, Tokyo, Japan, ⁵Department of Drug Policy & Management, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan, ⁶Center for Medical Statistics, Tokyo, Japan, ⁷Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Patients with Rheumatoid Arthritis (RA) experience loss of productivity such as missing their work and lowering their performance incurred by impaired physical functioning. Treatment…
Abstract Number: 610 • 2016 ACR/ARHP Annual Meeting
A Systematic Review and Meta-Analysis of Comparative Efficacy of Biologics in Treating Patients with Rheumatoid Arthritis: Assessment of Long-Term Radiographic Progression from Published Clinical Trials
Erin Murray¹, Yekaterina Butylkova¹, Alexandra Ellis¹, Martha Skup², Jasmina Kalabic³ and Vishvas Garg⁴, ¹Doctor Evidence, Santa Monica, CA, ²AbbVie Inc., North Chicago, IL, ³AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁴AbbVie Inc, North Chicago, IL
Background/Purpose: Previously, several studies have meta-analyzed clinical, functional or structural efficacy of biologics in treating rheumatoid arthritis (RA) patients. However, the comparative efficacy of biologics…
Abstract Number: 611 • 2016 ACR/ARHP Annual Meeting
Analysis of a German Subpopulation with Active Rheumatoid Arthritis Treated with Golimumab As Add-on Therapy to Disease-Modifying Antirheumatic Drugs
Hendrik Schulze-Koops¹, Jürgen Wollenhaupt², Marita Winnemöller³, Ines Klaudius³ and Helena Löffler³, ¹Division of Rheumatology, Division of Rheumatology and Clinical Immunology, Medizinische Klinik und Poliklinik IV, University of Munich, Munich, Germany, ²Schön Klinik Hamburg-Eilbek, Hamburg, Germany, ³Medical Affairs, MSD Sharp & Dohme GmbH, Haar, Germany
Background/Purpose: In previous clinical studies the human monoclonal TNFα-antibody golimumab (GLM) showed a good clinical response and a favorable benefit:risk profile in the treatment of…
Abstract Number: 612 • 2016 ACR/ARHP Annual Meeting
Long-Term Sustainability of TNF-Blocker Injection Spacing in Rheumatoid Arthritis: Results of a 3-Year Long-Term Observational Follow-up of a Tapering randomised Controlled Trial
Johanna Sigaux¹, Florian Bailly^2,3, Frédérique Gandjbakhch^1,3, Violaine Foltz^1,3, Florence Tubach^4,5, Laure Gossec^1,6 and Bruno Fautrel^1,7, ¹Rheumatology, Pitié Salpêtrière Hospital, Paris, France, ²rheumatology, Pitié Salpêtrière Hospital, paris, France, ³Sorbonne Universités, UPMC Univ Paris 06, Paris, France, Paris, France, ⁴Aix-Marseille University, Marseille, France, ⁵Université Pierre et Marie Curie (UPMC)-Paris 6; APHP, Pitié Salpêtrière Hospital, Département Biostatistics and Public health, Pharmacoepidémiology center (Cephepi), 7501875013, Paris, France ;, Paris, France, ⁶Sorbonne Universités, UPMC University Paris 06, Paris, France, Paris, France, ⁷GRC08, Sorbonne Universités, UPMC Univ Paris 06, Paris, France, Paris, France
Background/Purpose: Tapering of TNF blockers (TNFb) in rheumatoid arthritis (RA) patients in sustained remission is feasible in short-term randomized controlled trials (RCT). Less data are…
Abstract Number: 613 • 2016 ACR/ARHP Annual Meeting
Immunogenicity of Anti-TNF Therapies in Patients with Inflammatory Rheumatic Diseases and Secondary Failure: A Multicentre Study of 570 Patients
Alejandro Balsa¹, Raimon Sanmarti², José Rosas³, Susana Gomez Castro⁴, Ana Cabez⁴, Victor Martin⁴ and María Montoro⁴, ¹Rheumatology, IdiPAZ, Hospital Universitario La Paz, Madrid, Spain, ²Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ³Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ⁴Pfizer, Madrid, Spain
Abstract Immunogenicity of anti-TNF therapies in Patients with inflammatory rheumatic Diseases and secondary failure: a multicentre study of 570 patients. Background/Purpose: The treatment of…
Abstract Number: 614 • 2016 ACR/ARHP Annual Meeting
Canadian Study of Outcomes in Adalimumab (HUMIRA®) Patients with Support for Adherence – Results from the Companion Study
Sebastien Gerega¹, Brad Millson¹, Louis Bessette², John Marshall³, Gerald Lebovic^4,5, Michael Sung¹, Driss Oraichi¹, Sandra Gazel⁶, Tania Gaetano⁶, Martin Latour⁶ and Marie-Claude Laliberté⁶, ¹IMS Brogan, Kirkland, QC, Canada, ²Centre Hospitalier de l'Université Laval, Quebec, QC, Canada, ³Department of Medicine, Division of Gastroenterology, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada, ⁴Applied Health Research Centre, St. Michael’s Hospital, Toronto, ON, Canada, ⁵Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁶AbbVie, Inc., St.Laurent, QC, Canada
Background/Purpose: Adalimumab (ADA) is a TNF-alpha inhibitor indicated for use in various inflammatory autoimmune diseases including rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis…
Abstract Number: 615 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetic Similarity of ABP 710 Relative to Infliximab: Results from a Randomized, Single-Blind, Single-Dose, Parallel Group Study in Healthy Subjects
Primal Kaur¹, Vincent Chow², Nan Zhang³ and Eswar Krishnan⁴, ¹Amgen, Thousand Oaks, CA, ²Clinical Pharmacology, Amgen, Inc., Thousand Oaks, CA, ³Biosimilars, Amgen, Inc., Thousand Oaks, CA, ⁴Biosimilars, Amgen, Inc, Thousand Oaks, CA
Background/Purpose: Methods: Results: Pharmacokinetics: A total of 49 subjects received ABP 710 and 50 subjects received infliximab. Following a single dose, the adjusted…
Abstract Number: 616 • 2016 ACR/ARHP Annual Meeting
ABP 501 Long-Term Safety/Efficacy: Interim Results from an Open-Label Extension Study
Stanley Cohen¹, Jose L. Pablos², Nan Zhang³, Warren Rizzo⁴, Gerhard Muller⁵, Devi Padmanaban⁶, Alan Kivitz⁷, Alan K. Matsumoto⁸ and Primal Kaur⁹, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, ³Biosimilars, Amgen, Inc., Thousand Oaks, CA, ⁴Advanced Arthritis Care & Research, Scottsdale, AZ, ⁵Dept of Nephrology and Rheumatogy, University Medical Center Göttingen, Göttingen, NIEDERSACHSEN, Germany, ⁶Biosimilars, Amgen, Thousand Oaks, CA, ⁷Altoona Center for Clinical Research, Duncansville, PA, ⁸Rheumatology, Arthritis & Rheumatism Associate, Wheaton, MD, ⁹Amgen, Thousand Oaks, CA
Background/Purpose: This was a single-arm OLE of the parent study; the objective was to assess long-term safety and efficacy of ABP 501. The study…
Abstract Number: 617 • 2016 ACR/ARHP Annual Meeting
Therapy in Patients with Rheumatoid Arthritis (RA) with Inadequate Response to Tumor Necrosis Factor Alpha Inhibitors (TNFi): A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs
Maria A. Lopez-Olivo¹, Aliza Matusevich^2,3 and Maria Suarez-Almazor⁴, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine,The University of Texas MD Anderson Cancer Center, Houston, Texas, USA,, Houston, TX, ²General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³The University of Texas, School of Public Health, Houston, TX, ⁴Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Houston, TX
Background/Purpose: Up to one-third of the patients who receive TNFi lose responsiveness over time. Options available to these patients include treatment with an alternative TNFi…
Abstract Number: 618 • 2016 ACR/ARHP Annual Meeting
Do Canadian Rheumatologists Actually Treat to Target Once a Biologic Has Been Initiated? an Analysis from a Prospective, Observational Registry
Philip Baer¹, Andrew Chow², Michael Starr³, Boulos Haraoui⁴, Regan Arendse⁵, Michelle Teo⁶, Emmanouil Rampakakis⁷, Eliofotisti Psaradellis⁸, Allen J Lehman⁹, Francois Nantel¹⁰, Brendan Osborne¹¹, Cathy Tkaczyk¹¹ and Karina Maslova⁹, ¹Independent Rheumatology Practice, Scarborough, ON, Canada, ²Credit Valley Rheumatology, Mississauga, ON, Canada, ³Rheumatology, Mcgill University, Pointe-Claire,, QC, Canada, ⁴University of Montreal, Montreal, QC, Canada, ⁵University of Saskatchewan, Saskatoon, SK, Canada, ⁶Balfour Medical Clinic, Penticton, BC, Canada, ⁷JSS Medical Research, St-Laurent, QC, Canada, ⁸JSS Medical Research, Montreal, QC, Canada, ⁹Janssen Inc., Toronto, ON, Canada, ¹⁰19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Methods: Results: After 6 months of treatment, 46% of patients had achieved treatment target of remission or low DA, and 54% were…
Abstract Number: 619 • 2016 ACR/ARHP Annual Meeting
Concomitant Treatment Use during Treatment with Golimumab in Patients with Rheumatoid Arthritis
Philip Baer¹, Mary Bell², Boulos Haraoui³, Louis Bessette⁴, John Kelsall⁵, Maqbool Sheriff⁶, Emmanouil Rampakakis⁷, Eliofotisti Psaradellis⁸, Francois Nantel⁹, Allen J Lehman¹⁰, Brendan Osborne¹¹, Cathy Tkaczyk¹¹ and Karina Maslova¹⁰, ¹Independent Rheumatology Practice, Scarborough, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³University of Montreal, Montreal, QC, Canada, ⁴Rheumatology, CHUL de Quebec, Quebec, QC, Canada, ⁵Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁶Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁷JSS Medical Research, St-Laurent, QC, Canada, ⁸JSS Medical Research, Montreal, QC, Canada, ⁹19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Previous studies have shown that, when sustained good clinical response has been achieved with a biologic therapy, traditional disease-modifying anti-rheumatic drugs (DMARDs) and other…
Abstract Number: 620 • 2016 ACR/ARHP Annual Meeting
Clinical Activity, Ultrasound Assessment and Drug Monitoring in Rheumatoid Arthritis Patients Receiving Anti-TNF-α Therapy with Extended Interval of Administration
José Miguel Senabre-Gallego¹, José Rosas¹, Francisca Llinares-Tello², Mariana Marco-Mingot², Ana Pons¹, Xavier Barber³, Gregorio Santos-Soler¹, Esteban Salas-Heredia¹, Catalina Cano¹, Marisa Lorente⁴, Marina Sanchís³, Juan Molina², Mario García-Carrasco⁵ and AIRE-MB, ¹Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ²Laboratory, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ³CIO, Universidad Miguel Hernández, Elche, Spain, ⁴Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain, ⁵Systemic Autoimmune Diseases Research Unit, HGR 36-CIBIOR Instituto Mexicano del Seguro Social, Puebla, Mexico
Background/Purpose: To assess clinical activity, ultrasound synovitis and drug levels in rheumatoid arthritis (RA) patients receiving anti-TNFα therapy with extended interval of administration (EIA). Methods:…
Abstract Number: 621 • 2016 ACR/ARHP Annual Meeting
Effectiveness and Safety of CT- P13 (Biosimilar Reference Infliximab) in a Real-Life Setting in 151 Patients with Rheumatoid Arthritis and Ankylosing Spondylitis: A Mid-Term Interim Analysis
Catalin Codreanu¹, Klara Sirova², Katerina Jarosova³ and Anastas Batalov⁴, ¹Rheumatology, 'Dr. Ion Stoia' Clinical Center of Rheumatic Diseases, Bucharest, Romania, ²Revmatologie, Revmatologie MU Dr. Klara Sirova, sro, Ostrava, Czech Republic, ³Institute of Rheumatology, Prague, Czech Republic, ⁴Rheumatology, Medical University of Plovdiv, UMHAT Kaspela, Plovdiv, Bulgaria
Background/Purpose: Over the past decade, the use of biologics has significantly changed the management of rheumatoid arthritis (RA) and ankylosing spondylitis (AS). However, the high…
Abstract Number: 622 • 2016 ACR/ARHP Annual Meeting
Efficacy after Transition to SB5 from Reference Adalimumab (Humira®) Vs. Continuation of SB5 or Reference Adalimumab By Antibodies Developed after Transition from a SB5 Phase III Study
Mark C. Genovese¹, Michael Weinblatt², Edward C. Keystone³, Asta Baranauskaite⁴, Soo Yeon Cheong⁵ and Jeehoon Ghil⁵, ¹Stanford University Medical Center, Palo Alto, CA, ²Brigham and Women’s Hospital, Boston, MA, ³Mount Sinai Hospital, Toronto, ON, Canada, ⁴Lithuanian University of Health Sciences, Kaunas, Lithuania, ⁵Samsung Bioepis Co., Ltd., Incheon, South Korea
Background/Purpose : SB5 has been developed as a biosimilar of the reference adalimumab (ADL). The 52-week efficacy and safety results were reported previously. 1 Here…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].